Patents by Inventor Bruno Fuks

Bruno Fuks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for identifying agents that bind a levetiracetam binding site (LBS) or compete with LEV binding to a LBS of a synaptic vesicle protein 2 (SV2)
    Patent number: 7465549
    Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: December 16, 2008
    Assignee: UCB, S.A.
    Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks
  • Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
    Publication number: 20070135514
    Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.
    Type: Application
    Filed: December 2, 2003
    Publication date: June 14, 2007
    Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks
  • Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
    Patent number: 7090985
    Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam SV2 proteins, including SV2A.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: August 15, 2006
    Assignee: UCB, S.A.
    Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks
  • Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
    Publication number: 20040204388
    Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.
    Type: Application
    Filed: December 2, 2003
    Publication date: October 14, 2004
    Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks
  • Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
    Publication number: 20040106147
    Abstract: The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam SV2 proteins, including SV2A.
    Type: Application
    Filed: December 3, 2002
    Publication date: June 3, 2004
    Applicant: UCB, S.A.
    Inventors: Berkley Lynch, Karl Nocka, Bruno Fuks